Cite

    Russell, K. et al. (2022). A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults. Human vaccines & immunotherapeutics. 18 (5), p. . [Online].